{"id":740,"date":"2026-07-23T23:22:00","date_gmt":"2026-07-23T14:22:00","guid":{"rendered":"https:\/\/onepress.co.kr\/index.php\/briefing\/2026-07-23-casgevy-age-2-expanded-approval-en\/"},"modified":"2026-07-23T23:22:00","modified_gmt":"2026-07-23T14:22:00","slug":"2026-07-23-casgevy-age-2-expanded-approval-en","status":"publish","type":"briefing","link":"https:\/\/onepress.co.kr\/index.php\/briefing\/2026-07-23-casgevy-age-2-expanded-approval-en\/","title":{"rendered":"Casgevy expanded to age 2 and older, opening CRISPR therapy to younger patients"},"content":{"rendered":"<p><strong>2026-07-23 23:18 KST<\/strong><\/p>\n<p>The FDA issued a supplemental approval on 1 July 2026 for Casgevy (exagamglogene autotemcel) in certain patients aged 2 years and older with sickle cell disease or transfusion-dependent beta thalassemia. The key shift is a much younger US indication for a CRISPR-based gene therapy, not a simple treatment that every patient can immediately receive.<\/p>\n<h2>Who Is Affected<\/h2>\n<p>The expanded approval covers patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises, or transfusion-dependent beta thalassemia. FDA says Casgevy had previously been approved for patients aged 12 years and older with SCD or TDT. The change matters for families with younger children, but eligibility still depends on disease criteria, treatment history, transplant risk, and access to specialized centers.<\/p>\n<h2>What Changes<\/h2>\n<p>FDA issued the supplemental approval on 1 July 2026. FDA\u2019s Casgevy product page lists STN 125787 for patients aged 2 years and older with SCD with recurrent VOCs or TDT. FDA calls it the first gene therapy approved for patients aged 2 years and older with SCD. Vertex describes it as the first approved genetic therapy indicated for children as young as 2 for both SCD and TDT.<\/p>\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" src=\"https:\/\/onepress.co.kr\/wp-content\/uploads\/2026\/07\/casgevy-age-2-expanded-approval-en.png\" alt=\"Image explaining pediatric hematology counseling and a CRISPR stem-cell therapy pathway\" loading=\"eager\" \/><figcaption class=\"op-briefing-image-caption\">Produced image: ONEPRESS illustrates pediatric blood-disorder counseling and an autologous CRISPR-edited stem-cell therapy pathway. It is not an actual treatment scene or product promotion.<\/figcaption><\/figure>\n<h2>What The Therapy Is<\/h2>\n<p>Casgevy uses a patient\u2019s own hematopoietic stem cells, edits them with CRISPR\/Cas9, and returns them as a one-time intravenous infusion. FDA says the edited cells engraft in the bone marrow. That means this is not a pharmacy pill or routine outpatient injection; it involves cell collection, conditioning, intensive care planning, and long-term follow-up.<\/p>\n<h2>Limits And Cautions<\/h2>\n<p>The approval is a US decision, and age or disease indications can differ by country. It also does not mean every child with SCD or TDT is eligible. Families need specialist review of disease severity, prior therapies, infection and transplant risks, fertility preservation counseling, and follow-up plans. FDA product documents and approval letters are the starting point.<\/p>\n<h2>Official Checks<\/h2>\n<p>Use the FDA announcement for the date, age expansion, and first pediatric SCD gene-therapy scope. Use FDA\u2019s Casgevy product page for STN 125787 indication, package insert, and approval letter. Use Vertex\u2019s release to cross-check manufacturer framing and SCD\/TDT wording.<\/p>\n<h2>Official sources<\/h2>\n<p><a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapy-young-children-sickle-cell-disease\" target=\"_blank\" rel=\"noopener noreferrer\">FDA release: approval date, age expansion, and first pediatric SCD gene-therapy scope<\/a><\/p>\n<p><a href=\"https:\/\/www.fda.gov\/vaccines-blood-biologics\/casgevy\" target=\"_blank\" rel=\"noopener noreferrer\">FDA Casgevy page: STN 125787 indication and approval documents<\/a><\/p>\n<p><a href=\"https:\/\/investors.vrtx.com\/news-releases\/news-release-details\/vertex-announces-us-fda-approval-expanded-use-casgevyr-treatment\" target=\"_blank\" rel=\"noopener noreferrer\">Vertex release: manufacturer explanation of expanded indication<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The FDA issued a supplemental approval on 1 July 2026 for Casgevy (exagamglogene autotemcel) in certain patients aged 2 years and older with sickle cell disease or transfusion-dependent beta thalassemia. The key shift is a much younger US indication for a CRISPR-based gene therapy, not a simple treatment that every patient can immediately receive.<\/p>\n","protected":false},"featured_media":0,"template":"","meta":[],"class_list":["post-740","briefing","type-briefing","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/onepress.co.kr\/index.php\/wp-json\/wp\/v2\/briefing\/740","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/onepress.co.kr\/index.php\/wp-json\/wp\/v2\/briefing"}],"about":[{"href":"https:\/\/onepress.co.kr\/index.php\/wp-json\/wp\/v2\/types\/briefing"}],"wp:attachment":[{"href":"https:\/\/onepress.co.kr\/index.php\/wp-json\/wp\/v2\/media?parent=740"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}